Holen Sie sich die Stockscreener-App
185.78
0.93%
1.71
Handel nachbörslich:
186.50
0.72
+0.39%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca reportedly hit by serious cyberattack - pharmaphorum
AstraZeneca PLC (AZN) gains after successful Saphnelo trial - MSN
Astrazeneca plc Announces In-Licensing of Worldwide Rights from Astrazeneca to A Phase 3?Ready Novel Chemical Entity - marketscreener.com
AstraZeneca Data Breach: What You Need to Know - SOCRadar® Cyber Intelligence Inc.
Westview Management dba Westview Investment Advisors Invests $3.60 Million in Astrazeneca Plc $AZN - MarketBeat
Gradient Investments LLC Has $16.96 Million Holdings in Astrazeneca Plc $AZN - MarketBeat
LAPSUS$ Hackers Claim Breach of AstraZeneca’s Internal Systems - cyberpress.org
J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a £140 PT - MSN
AstraZeneca Data BreachLAPSUS$ Group Allegedly Claims Access to Internal Data - CyberSecurityNews
AstraZeneca PLC stock faces March pressure amid 100% YTD surge on NYSE - AD HOC NEWS
Signet Financial Management LLC Invests $2.57 Million in Astrazeneca Plc $AZN - MarketBeat
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
AstraZeneca plc stock faces pressure amid monthly declines but shows YTD strength in volatile pharma - AD HOC NEWS
Patterns Watch: Whats the outlook for AstraZeneca PLC Depositary Receipts sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn
Hilltop National Bank Purchases 7,586 Shares of Astrazeneca Plc $AZN - MarketBeat
QP Wealth Management LLC Buys New Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Hacker Group LAPSUS$ Claims Alleged AstraZeneca Data Breach - Hackread
Form 6K AstraZeneca PLC ADR For: 20 March By Investing.com - Investing.com South Africa
AstraZeneca’s Pan-HER2 China Study Builds a Quiet Long-Term Edge in Oncology - TipRanks
AstraZeneca, Sanofi expand R&D footprint in China (AZN:NYSE) - Seeking Alpha
AstraZeneca admits 45,750 new shares to London Stock Exchange main market - Investing.com
AstraZeneca (AZN) admits 45,750 new employee scheme shares to LSE - Stock Titan
Park National Corp OH Has $12.82 Million Stock Position in Astrazeneca Plc $AZN - MarketBeat
Miller Global Investments LLC Buys Shares of 7,716 Astrazeneca Plc $AZN - MarketBeat
2 Healthcare Stocks to Buy Before They Get Bought Out - The Motley Fool
Astrazeneca (NYSE:AZN) Rating Increased to Buy at Wall Street Zen - MarketBeat
AstraZeneca PLC stock faces pressure on NYSE amid insider filings and China expansion news - AD HOC NEWS
Moody's Changes Outlook on AstraZeneca to Positive on Organic Track Record - marketscreener.com
AstraZeneca (AZN) officer Mani Sharma details share and award holdings - Stock Titan
AstraZeneca Expands Real-World Push With New China Kidney Registry - TipRanks
AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook - TipRanks
AstraZeneca to boost cell therapy capabilities with new China investment - BioPharma Dive
Wilmington Savings Fund Society FSB Cuts Stock Position in Astrazeneca Plc $AZN - MarketBeat
Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca to build cell therapy base, innovation centre in Shanghai - marketscreener.com
AstraZeneca Makes Soliris Available In Malaysia For Rare Disease Treatment - bernama
Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026 - Meyka
AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer - Smartkarma
Why AstraZeneca Stock Was a Winner Today - MSN
AstraZeneca (AZN) Price Target Backed by Goldman After Baxdrostat Phase 3 Data - MSN
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims - GuruFocus
AZN Stock Quote Price and Forecast - CNN
Why AstraZeneca PLC (AZN) is one of the best immunotherapy stocks to buy according to hedge funds - MSN
Astrazeneca Plc $AZN Shares Sold by CIBC Private Wealth Group LLC - MarketBeat
AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach - TipRanks
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU - Yahoo Finance
Imfinzi EU Approval Expands AstraZeneca Gastric Cancer Reach For Investors - Yahoo Finance
AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical - MSN
Sentiment Recap: Why is AstraZeneca PLC Depositary Receipt stock going up2026 Market Trends & Fast Gain Swing Alerts - baoquankhu1.vn
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Rul - GuruFocus
Andrew Hamilton Acquires Omeprazole.com From AstraZeneca, Expanding Strategic Pharmaceutical Domain Portfolio - Yahoo Finance
Can AstraZeneca PLC Depositary Receipt expand into new marketsTrend Reversal & Real-Time Stock Entry Alerts - baoquankhu1.vn
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp - Insider Monkey
AstraZeneca receives EU approval for Imfinzi in early gastric cancer By Investing.com - Investing.com South Africa
AstraZeneca's Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer -- Update - marketscreener.com
EU backs AstraZeneca (NYSE: AZN) Imfinzi for early gastric and GEJ cancers - Stock Titan
AstraZeneca (AZN) Gains EU Approval for Imfinzi in Cancer Treatm - GuruFocus
AstraZeneca PLC Stock (ISIN: US6549022043) Gains Momentum on EU Imfinzi Approval for Gastric Cancer - AD HOC NEWS
EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer - marketscreener.com
Holocene Advisors LP Acquires 1,807,565 Shares of Astrazeneca Plc $AZN - MarketBeat
Fayez Sarofim & Co Has $298.78 Million Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca's Imfinzi receives EU approval - Sharecast.com
Centiva Capital LP Takes Position in Astrazeneca Plc $AZN - MarketBeat
0.60%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):